967 related articles for article (PubMed ID: 27885838)
1. Osimertinib for EGFR T790M mutation-positive non-small cell lung cancer.
Soejima K; Yasuda H; Hirano T
Expert Rev Clin Pharmacol; 2017 Jan; 10(1):31-38. PubMed ID: 27885838
[TBL] [Abstract][Full Text] [Related]
2. Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer.
Soria JC; Ohe Y; Vansteenkiste J; Reungwetwattana T; Chewaskulyong B; Lee KH; Dechaphunkul A; Imamura F; Nogami N; Kurata T; Okamoto I; Zhou C; Cho BC; Cheng Y; Cho EK; Voon PJ; Planchard D; Su WC; Gray JE; Lee SM; Hodge R; Marotti M; Rukazenkov Y; Ramalingam SS;
N Engl J Med; 2018 Jan; 378(2):113-125. PubMed ID: 29151359
[TBL] [Abstract][Full Text] [Related]
3. Preclinical Comparison of Osimertinib with Other EGFR-TKIs in EGFR-Mutant NSCLC Brain Metastases Models, and Early Evidence of Clinical Brain Metastases Activity.
Ballard P; Yates JW; Yang Z; Kim DW; Yang JC; Cantarini M; Pickup K; Jordan A; Hickey M; Grist M; Box M; Johnström P; Varnäs K; Malmquist J; Thress KS; Jänne PA; Cross D
Clin Cancer Res; 2016 Oct; 22(20):5130-5140. PubMed ID: 27435396
[TBL] [Abstract][Full Text] [Related]
4. Loss of T790M mutation is associated with early progression to osimertinib in Chinese patients with advanced NSCLC who are harboring EGFR T790M.
Zhao S; Li X; Zhao C; Jiang T; Jia Y; Shi J; He Y; Li J; Zhou F; Gao G; Li W; Chen X; Su C; Ren S; Zhou C
Lung Cancer; 2019 Feb; 128():33-39. PubMed ID: 30642450
[TBL] [Abstract][Full Text] [Related]
5. A Phase II Trial of Osimertinib in the Second-Line Treatment of Non-small Cell Lung Cancer with the EGFR T790M Mutation, Detected from Circulating Tumor DNA: LiquidLung-O-Cohort 2.
Park CK; Cho HJ; Choi YD; Oh IJ; Kim YC
Cancer Res Treat; 2019 Apr; 51(2):777-787. PubMed ID: 30189719
[TBL] [Abstract][Full Text] [Related]
6. Third-generation inhibitors targeting EGFR T790M mutation in advanced non-small cell lung cancer.
Wang S; Cang S; Liu D
J Hematol Oncol; 2016 Apr; 9():34. PubMed ID: 27071706
[TBL] [Abstract][Full Text] [Related]
7. Osimertinib in the treatment of patients with epidermal growth factor receptor T790M mutation-positive metastatic non-small cell lung cancer: clinical trial evidence and experience.
Sullivan I; Planchard D
Ther Adv Respir Dis; 2016 Dec; 10(6):549-565. PubMed ID: 27784815
[TBL] [Abstract][Full Text] [Related]
8. Safety of osimertinib in EGFR-mutated non-small cell lung cancer.
Mezquita L; Varga A; Planchard D
Expert Opin Drug Saf; 2018 Dec; 17(12):1239-1248. PubMed ID: 30457891
[TBL] [Abstract][Full Text] [Related]
9. [Osimertinib (Tagrisso
Giroux Leprieur E; Cortot AB; Cadranel J; Wislez M
Bull Cancer; 2016 Oct; 103(10):815-821. PubMed ID: 27641462
[TBL] [Abstract][Full Text] [Related]
10. Osimertinib: A third-generation tyrosine kinase inhibitor for treatment of epidermal growth factor receptor-mutated non-small cell lung cancer with the acquired Thr790Met mutation.
Bollinger MK; Agnew AS; Mascara GP
J Oncol Pharm Pract; 2018 Jul; 24(5):379-388. PubMed ID: 28565936
[TBL] [Abstract][Full Text] [Related]
11. Osimertinib (AZD9291) and CNS Response in Two Radiotherapy-Naïve Patients with EGFR-Mutant and T790M-Positive Advanced Non-Small Cell Lung Cancer.
Ricciuti B; Chiari R; Chiarini P; Crinò L; Maiettini D; Ludovini V; Metro G
Clin Drug Investig; 2016 Aug; 36(8):683-6. PubMed ID: 27177916
[TBL] [Abstract][Full Text] [Related]
12. Audit of Molecular Mechanisms of Primary and Secondary Resistance to Various Generations of Tyrosine Kinase Inhibitors in Known Epidermal Growth Factor Receptor-Mutant Non-small Cell Lung Cancer Patients in a Tertiary Centre.
Suryavanshi M; Jaipuria J; Mattoo S; Dhandha S; Khatri M
Clin Oncol (R Coll Radiol); 2022 Nov; 34(11):e451-e462. PubMed ID: 35810049
[TBL] [Abstract][Full Text] [Related]
13. Osimertinib for the treatment of patients with
Alsharedi M; Bukamur H; Elhamdani A
Drugs Today (Barc); 2018 Jun; 54(6):369-379. PubMed ID: 29998228
[TBL] [Abstract][Full Text] [Related]
14. Targeting EGFR in Lung Cancer: Current Standards and Developments.
Díaz-Serrano A; Gella P; Jiménez E; Zugazagoitia J; Paz-Ares Rodríguez L
Drugs; 2018 Jun; 78(9):893-911. PubMed ID: 29915896
[TBL] [Abstract][Full Text] [Related]
15. Impact of the generation of EGFR-TKIs administered as prior therapy on the efficacy of osimertinib in patients with non-small cell lung cancer harboring EGFR T790M mutation.
Miyashita Y; Ko R; Shimada N; Mitsuishi Y; Miura K; Matsumoto N; Asao T; Shukuya T; Shibayama R; Koyama R; Takahashi K
Thorac Cancer; 2021 Feb; 12(3):329-338. PubMed ID: 33219754
[TBL] [Abstract][Full Text] [Related]
16. Rapid intracranial response to osimertinib, without radiotherapy, in nonsmall cell lung cancer patients harboring the EGFR T790M mutation: Two Case Reports.
Koba T; Kijima T; Takimoto T; Hirata H; Naito Y; Hamaguchi M; Otsuka T; Kuroyama M; Nagatomo I; Takeda Y; Kida H; Kumanogoh A
Medicine (Baltimore); 2017 Feb; 96(6):e6087. PubMed ID: 28178168
[TBL] [Abstract][Full Text] [Related]
17. Osimertinib, a third-generation tyrosine kinase inhibitor targeting non-small cell lung cancer with EGFR T790M mutations.
McCoach CE; Jimeno A
Drugs Today (Barc); 2016 Oct; 52(10):561-568. PubMed ID: 27910964
[TBL] [Abstract][Full Text] [Related]
18. The safety and efficacy of osimertinib for the treatment of EGFR T790M mutation positive non-small-cell lung cancer.
Gao X; Le X; Costa DB
Expert Rev Anticancer Ther; 2016; 16(4):383-90. PubMed ID: 26943236
[TBL] [Abstract][Full Text] [Related]
19. Understanding Mechanisms of Resistance in the Epithelial Growth Factor Receptor in Non-Small Cell Lung Cancer and the Role of Biopsy at Progression.
Socinski MA; Villaruz LC; Ross J
Oncologist; 2017 Jan; 22(1):3-11. PubMed ID: 27821794
[TBL] [Abstract][Full Text] [Related]
20. Osimertinib for the treatment of non-small cell lung cancer.
Sun JM; Lee SH; Ahn JS; Park K; Ahn MJ
Expert Opin Pharmacother; 2017 Feb; 18(2):225-231. PubMed ID: 28116908
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
